Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tisagenlecleucel in first-line high-risk pediatric and young adult B-ALL with end-of-consolidation MRD positivity
NL-OMON54738Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Nov 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tisagenlecleucel in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Novartis. Primary endpoints: Overall survival, 5-year disease-free survival without censoring for new anticancer therapy and 1 more. Started Nov 2019; status: recruiting.
02
Drugs
tisagenlecleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NL-OMON54738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54738.